Stock Ratings / Health Care / TPST / options

GDTC (54) LSTA (32) LTRN (42) BLRX (60) ⌘ Pro Terminal →

Tempest Therapeutics Inc. (TPST) Options Positioning, Max Pain & Unusual Sweeps

Q: What is TPST's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for TPST.

$0.53 -1.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Tempest Therapeutics Inc. (TPST) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $10.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TPST)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (TPST)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for TPST.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TPST)

✓Walkthrough of TPST's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TPST // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.37%📐 HORIZONTAL RANGE

2026-10-30O $0.53H $0.55L $0.49C $0.53VOL 150.4K

RES: $1.57SUP: $0.14SMA50: $0.82SMA200: $1.50

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TPST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TPST Butterfly Map → + Track TPST →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TPST today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TPST. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TPST today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TPST)

Health Care Rank #526 of 1016 ⚔️ GDTC vs TPST Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TPST vs. GDTC, LSTA, LTRN, BLRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Tempest Therapeutics Inc. (TPST) ranks #526 by composite RQD confidence (44/100, grade D) and #892 by equity capitalization ($10.7M). Within this direct 5-issuer industry benchmark cohort, TPST leads on earnings valuation at N/A trailing P/E, while TPST leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with TPST at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TPST ACTIVE Tempest Therapeutics Inc.	D	44/100	—	—	-35.0%	-1.24%	$10.7M	Benchmark Subject
GDTC CytoMed Therapeutics Limited	D+	54/100	—	—	—	-3.68%	$10.7M	/gdtc-vs-tpst →
LSTA Lisata Therapeutics Inc.	E	32/100	—	—	-35.0%	-4.72%	$10.9M	/lsta-vs-tpst →
LTRN Lantern Pharma Inc.	D-	42/100	—	—	-35.0%	-5.52%	$10.9M	/ltrn-vs-tpst →
BLRX BioLineRx Ltd.	C-	60/100	—	—	—	+1.00%	$10.1M	/blrx-vs-tpst →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001544227

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tempest Therapeutics Inc. (TPST) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$26.3M, operating cash flow of -$26.8M, and free cash flow of -$26.8M (+19.8% YoY). On the balance sheet, TPST closed FY2025 with $16.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$26.3M	-$26.8M	-$26.8M	$16.9M	—
FY2024 (FY)	2024-12-31	$0	-$41.8M	-$33.0M	-$33.5M	$41.5M	$0
FY2023 (FY)	2023-12-31	$0	-$29.5M	-$27.4M	-$27.4M	—	—

3. TPST Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TPST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Tempest Therapeutics Inc. (NASDAQ: TPST) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.53 (-1.24% 1D, market cap $10.7M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TPST ranks #526 in composite RQD confidence.

How does TPST compare to GDTC and LSTA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TPST carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GDTC (CytoMed Therapeutics Limited) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $10.7M) and LSTA (Lisata Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $10.9M). Among the 5-stock peer group, TPST leads on earnings multiple (N/A) while TPST leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TPST?

Per TPST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001544227), Tempest Therapeutics Inc. generated $0 in revenue, -$26.3M in net income, and -$26.8M in free cash flow against $16.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TPST trading relative to its 50-day, 200-day, and 52-week technical levels?

TPST last traded at $0.53 (-1.24% on volume of 57,159 shares), positioning the stock -35.37% below its 50-day simple moving average ($0.82) and -64.67% below its 200-day simple moving average ($1.50). Across its 52-week range of $0.49 to $10.45, TPST sits at the 0.4% percentile with a 14-day RSI of 29.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.60).

TPST Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is TPST's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for TPST.

Direct Sub-Reports: TPST RQD Cockpit TPST 12M Forecast TPST Earnings & Move TPST Dividends & DRIP TPST Insiders & 13F TPST Whale Options TPST Profit Sankey TPST News & Why